{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910780901103321"]
[null,null,"Titolo",null,"Diseases of importance in the United States / / by the Committee on Issues and Priorities for New Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academy Press, 1985"]
[null,null,"ISBN",null,"1-281-30039-X"]
[{"$nulls":4},"9786611300395"]
[{"$nulls":4},"0-309-11575-2"]
[null,null,"Descrizione fisica",null,"1 online resource (472 pages)"]
[null,null,"Collana",null,"New vaccine development : establishing priorities ; ; v. 1"]
[null,null,"Disciplina",null,"614.4/7/0973"]
[null,null,"Soggetti",null,"Vaccines - Research - Government policy"]
[{"$nulls":4},"Vaccination - United States"]
[{"$nulls":4},"Vaccination - Developing countries"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Prepared for the National Institute of Allergy and Infectious Diseases."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"Title\"\"; \"\"Copyright\"\"; \"\"Acknowledgments\"\"; \"\"Preface\"\"; \"\"Abstract\"\"; \"\"Contents\"\"; \"\"1 Summary\"\"; \"\"Selection of Candidates\"\"; \"\"Determination of Health Benefits\"\"; \"\"Disease Burden Estimates\"\"; \"\"Infant Mortality Equivalence Values\"\"; \"\"Total Disease Burden Values\"\"; \"\"Vaccine Characteristics\"\"; \"\"Predictions of Vaccine Development\"\"; \"\"Definition of Probable Vaccine Target Population\"\"; \"\"Estimation of Vaccine Utilization\"\"; \"\"Estimation of Time to Licensure, Time to vaccine Adoption, and Delay of Vaccination Benefits: Discounting\"\"; \"\"Estimation of vaccine Preventable Illness\"\""]
[{"$nulls":4},"\"\"Calculation of Expected Health Benefits for Each Vaccine\"\" \"\"Cost Calculations\"\"; \"\"Calculation of Morbidity Costs Averted by the Vaccine\"\"; \"\"Vaccination Program Costs\"\"; \"\"Integration of Costs\"\"; \"\"Interpretation of Health Benefit and Net Cost Rankings\"\"; \"\"Findings, Conclusions, Recommendations\"\"; \"\"Recommendation\"\"; \"\"Reference\"\"; \"\"2 Priority Setting for Health Related Investments: A Review of Methods\"\"; \"\"Methods for Project Ranking and Selection\"\"; \"\"Multiattribute Accounting\"\"; \"\"Multiattribute Scoring\"\"; \"\"Decision Analysis With Multiple Objectives\"\""]
[{"$nulls":4},"\"\"Cost-Effectiveness and Cost-Utility Analysis\"\" \"\"Benefit-Cost Analysis\"\"; \"\"Selection of an Approach\"\"; \"\"Issues in Project Ranking Methodologies\"\"; \"\"Sources of Estimates\"\"; \"\"Sequential or "]
[{"$nulls":4},"'Lexicographic' Methods\"\"; \"\"Interdependence Among Projects\"\"; \"\"The 'Portfolio' Question\"\"; \"\"Summary\"\"; \"\"References\"\"; \"\"3 Overview of the Analytic Approach\"\"; \"\"Method\"\"; \"\"Interpretation of Results\"\"; \"\"Guidelines\"\"; \"\"Definition of Dominance\"\"; \"\"Step 1\"\"; \"\"Step 2\"\"; \"\"Step 3\"\"; \"\"Step 4\"\"; \"\"Summary\"\"; \"\"4 Comparison of Disease Burdens and Costs\"\""]
[{"$nulls":4},"\"\"Elements of the System for Comparing Morbidity and Mortality Burdens Arising From various Diseases\"\" \"\"Trade-Off Values\"\"; \"\"Expression of Morbidity and Mortality Burdens\"\"; \"\"Procedures Used in Deriving Disease Estimates\"\"; \"\"Limitations of the Current Estimates\"\"; \"\"Value Judgments in Quantifying Morbidity and Mortality\"\"; \"\"IME Perspectives used in This Study\"\"; \"\"The Effect of Adopting Other IME Perspectives\"\"; \"\"Comparison of Direct Costs Resulting from Diseases\"\"; \"\"Scope of Cost Calculations\"\"; \"\"Procedures\"\"; \"\"Findings\"\"; \"\"Limitations of the Proposed System\"\""]
[{"$nulls":4},"\"\"Summary and Conclusions\"\" \"\"Recommendations\"\"; \"\"References\"\"; \"\"5 Predictions on Vaccine Development\"\"; \"\"The Need for Predictions\"\"; \"\"Selection of Candidates\"\"; \"\"Vaccine Candidates and Target Populations\"\"; \"\"Predictions on Vaccine Development\"\"; \"\"Probability of Successful Development\"\"; \"\"Cost of Development\"\"; \"\"Time to Licensure\"\"; \"\"Comments\"\"; \"\"Predictions on Vaccine Characteristics\"\"; \"\"Efficacy\"\"; \"\"Adverse Reactions\"\"; \"\"Production Technology, Delivery Requirements, and Cost/Dose\"\"; \"\"Number of Doses and Route of Administration\"\"; \"\"Conclusions\"\"; \"\"6 Assessing the Likely Utilization of New Vaccines\"\""]